Post-ERCP Acute Pancreatitis Clinical Trial
Official title:
A Prospective, Multi-center, Investigator Sponsored, Randomized Controlled Trial-- The Prophylactic Effect of Stilamin on Post-ERCP Pancreatitis
Pancreatitis are one of the most common complications of post-ERCP (Endoscopic Retrograde Cholangiopancreatography), the incidence rate is 5&-10%, how to prevent PEP and hyperamylasemia is an important issue, somatostatin is widely used in the field of pancreas treatment. In order to explore the effects of somatostatin on prevent PEP(post-ERCP Pancreatitis), 908 subjects will be enrolled in two group in the study, one group is given common treatment, the other uses somatostatin in the base of common treatment.
A prospective, multi-center, investigator sponsored, randomized controlled trial, 15 sites
join in in China, 908 subjects will be enrolled.
A descriptive analysis will be performed on primary endpoint, containing frequency of number
and percentage of patients. A two proportion equality test will be conducted to explore
whether incidence rates are different.
Descriptive statistics including number (N), mean, median, standard deviation, minimum and
maximum, will be produced for all continuous variables. Frequency tables of number (N) and
percentage of subjects will be produced for all categorical variables.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04546867 -
Establishing a Sonographic Based Algorithm to Verify Pancreatic Stent Position Placed to Prevent Post-ERCP Pancreatitis Before Endoscopic Removal
|
N/A | |
Terminated |
NCT02241512 -
IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis
|
Phase 2 | |
Completed |
NCT00222092 -
Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers
|
Phase 4 | |
Completed |
NCT05310409 -
PAN-PROMISE to Detect Post-ERCP Pancreatitis Symptoms
|
||
Not yet recruiting |
NCT06260878 -
Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis
|
Phase 4 | |
Not yet recruiting |
NCT04770857 -
Evaluation of Post-ERCP Pain as a Predictor for Post-ERCP Pancreatitis
|
||
Completed |
NCT02641561 -
Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
|
Phase 3 | |
Active, not recruiting |
NCT04145336 -
7 cm vs. 5 cm Pancreatic Stents for the Prevention of Post-ERCP Pancreatitis in High-risk Patients
|
N/A | |
Completed |
NCT03629600 -
Trial of Aggressive Hydration Versus Rectal Indomethacin for Prevention of Post-ERCP Pancreatitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT03756116 -
Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide
|
N/A | |
Recruiting |
NCT05664074 -
Rectal Indomethacin vs Intravenous Ketorolac
|
Phase 4 | |
Completed |
NCT02308891 -
A Prospective Trial of Aggressive Hydration Strategy to Reduce Post-ERCP Pancreatitis
|
N/A | |
Recruiting |
NCT05336630 -
Study of Forceps Cannulation During ERCP
|
N/A | |
Recruiting |
NCT05857514 -
Randomized Controlled Trial of Rectal Indomethacin Versus Combined Pancreatic Stent Placement and Rectal Indomethacin for Preventing Post-ERCP Pancreatitis
|
N/A | |
Recruiting |
NCT05267379 -
An European Multi-centre Cohort Study for Unravelling Pharmacokinetic and Genetic Factors Underlying Post-ERCP Pancreatitis
|
||
Recruiting |
NCT05947461 -
Prevention of Post-ERCP Pancreatitis by Indomethacin vs Diclofenac
|
N/A | |
Completed |
NCT03098082 -
Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis
|
N/A | |
Recruiting |
NCT02830984 -
ENBD After Endoscopic Sphincterotomy Plus Large-balloon Dilation for Preventing PEP
|
N/A | |
Recruiting |
NCT02839356 -
Epinephrine Sprayed on the Papilla for the Prevention of Post-ERCP Pancreatitis
|
Phase 4 | |
Completed |
NCT01673763 -
Post-ERCP Pancreatitis Prevention by Stent Insertion
|
N/A |